SCYNEXIS (SCYX) Price & Analysis

Compare

1,559 Followers

SCYX Stock Chart & Stats

$0.63

-$0.06(-4.73%)

At close: Jan 08 4:00 PM EST

$0.63

-$0.06(-4.73%)

Day’s Range― - ―

52-Week Range$0.57 - $1.49

Previous CloseN/A

Volume100.07K

Average Volume (3M)612.75K

Market Cap

$26.49M

Enterprise Value-$8.96M

Total Cash (Recent Filing)$38.01M

Total Debt (Recent Filing)$2.28M

Price to Earnings (P/E)―

Beta1.35

Next Earnings

Apr 01, 2026

EPS Estimate

0.13

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.17

Shares Outstanding41,965,057

10 Day Avg. Volume689,890

30 Day Avg. Volume612,753

Financial Highlights & Ratios

PEG Ratio0.02

Price to Book (P/B)1.07

Price to Sales (P/S)15.67

P/FCF Ratio-2.44

Enterprise Value/Market Cap-0.34

Enterprise Value/Revenue-3.06

Enterprise Value/Gross Profit-3.06

Enterprise Value/Ebitda-4.17

Forecast

1Y Price Target

$3.50

Price Target Upside455.56% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Financial StabilityScynexis should be well-funded into mid-2027.

Innovation And DevelopmentScynexis remains focused on advancing its next-generation antifungal, SCY-247, into a P2 study targeting invasive candidiasis, following positive P1 data supporting its safety and potential efficacy.

Partnership And MilestonesThe Brexafemme relaunch is progressing with GSK, with Scynexis eligible for up to ~$146M in annual sales milestones plus low-mid single-digit royalties.

Bears Say

Development OvershadowingThe activity around ibrexa and GSK has overshadowed the development activity around SCY-247.

Market ReactionSCYX shares are down ~25% on the news, which we believe stems from a sell-the-news mentality.

SCYNEXIS News

Scynexis completes transfer of BREXAFEMME NDA to GSK

SCYNEXIS (SCYX) announced that it has completed the transfer of the BREXAFEMME New Drug Application, NDA, to GSK...

30d ago

GSK

SCYX

Scynexis announces grant for Hackensack Meridian, Johns Hopkins collaboration

SCYNEXIS (SCYX) announced that a novel series of antifungal compounds utilizing SCYNEXIS’ proprietary triterpenoid antifungal platform are among...

1M ago

SCYX

SCYNEXIS: Strong Financial Position and Promising Antifungal Pipeline Drive Buy Rating

SCYNEXIS, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason McCarthy from Maxim...

1M ago

SCYX

SCYNEXIS Reports Q3 2025 Financial Results and Strategic Updates

SCYNEXIS Inc ( ($SCYX) ) has released its Q3 earnings. Here is a breakdown of the information SCYNEXIS...

1M ago

SCYX

Scynexis reports Q3 EPS (17c), consensus (20c)

Reports Q3 revenue $334,000, consensus $147,670. “Over the last several weeks, SCYNEXIS (SCYX) realized two significant achievements that...

1M ago

SCYX

SCYX Upcoming Earnings Report: What to Expect?

SCYNEXIS Inc (SCYX) is scheduled to report 3rd quarter earnings on 11/05/2025. Regarding Q3 estimates, Wall Street analysts...

2M ago

SCYX

Scynexis price target lowered to $3 from $4 at Guggenheim

Guggenheim lowered the firm’s price target on Scynexis (SCYX) to $3 from $4 and keeps a Buy rating...

2M ago

GSK

SCYX

SCYNEXIS: Strategic Advancements and Financial Stability Drive Buy Rating

Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on SCYNEXIS. The associated price target remains...

2M ago

SCYX

SCYNEXIS and GSK Amend License Agreement

SCYNEXIS ( ($SCYX) ) has shared an update. On October 14, 2025, SCYNEXIS and GSK signed a binding...

2M ago

SCYX

Scynexis, GSK resolve disagreement related to restart of Phase 3 MARIO study

SCYNEXIS (SCYX) announced that it will receive a $22 million payment from GlaxoSmithKline Intellectual Property as part of...

2M ago

SCYX

Buy Rating on SCYNEXIS: Promising Potential of SCY-247 Amid Market Volatility

In a report released yesterday, Jason McCarthy from Maxim Group reiterated a Buy rating on SCYNEXIS, with a...

3M ago

SCYX

Scynexis announces results from Phase 1 SAD/MAD study of SCY-247

SCYNEXIS (SCYX) announced results from a Phase 1 study of SCY-247, its second-generation triterpenoid antifungal under development for...

3M ago

SCYX

Promising Potential of SCY-247: A Game-Changer in Antifungal Treatment

Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on SCYNEXIS. The associated price target remains...

3M ago

SCYX

Scynexis announces presentations highlighting data on SCY-247

SCYNEXIS (SCYX) announced multiple upcoming presentations highlighting data on the Company’s second-generation fungerp drug candidate, SCY-247, at the...

4M ago

SCYX

SCYX FAQ

What was SCYNEXIS’s price range in the past 12 months?

SCYNEXIS lowest stock price was $0.56 and its highest was $1.49 in the past 12 months.

What is SCYNEXIS’s market cap?

SCYNEXIS’s market cap is $26.49M.

When is SCYNEXIS’s upcoming earnings report date?

SCYNEXIS’s upcoming earnings report date is Apr 01, 2026 which is in 103 days.

How were SCYNEXIS’s earnings last quarter?

SCYNEXIS released its earnings results on Nov 05, 2025. The company reported -$0.17 earnings per share for the quarter, beating the consensus estimate of -$0.2 by $0.03.

Is SCYNEXIS overvalued?

According to Wall Street analysts SCYNEXIS’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does SCYNEXIS pay dividends?

SCYNEXIS does not currently pay dividends.

What is SCYNEXIS’s EPS estimate?

SCYNEXIS’s EPS estimate is 0.13.

How many shares outstanding does SCYNEXIS have?

SCYNEXIS has 41,965,057 shares outstanding.

What happened to SCYNEXIS’s price movement after its last earnings report?

SCYNEXIS reported an EPS of -$0.17 in its last earnings report, beating expectations of -$0.2. Following the earnings report the stock price went down -4.762%.

Which hedge fund is a major shareholder of SCYNEXIS?

Currently, no hedge funds are holding shares in SCYX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

SCYNEXIS

SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

SCYNEXIS (SCYX) Earnings & Revenues

Historic Earnings Reports

SCYX Stock 12 Month Forecast

Average Price Target

$3.50

▲(455.56% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","5":"$5","-1":"-$1","0.5":"$0.5","3.5":"$3.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$4.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$3.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$3.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0.5,2,3.5,5],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.66,0.916923076923077,1.1738461538461538,1.4307692307692308,1.6876923076923078,1.9446153846153846,2.2015384615384614,2.4584615384615387,2.7153846153846155,2.9723076923076923,3.229230769230769,3.4861538461538464,3.743076923076923,{"y":4,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.66,0.8784615384615385,1.096923076923077,1.3153846153846154,1.5338461538461539,1.7523076923076921,1.9707692307692306,2.189230769230769,2.4076923076923076,2.626153846153846,2.8446153846153845,3.063076923076923,3.2815384615384615,{"y":3.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.66,0.8400000000000001,1.02,1.2000000000000002,1.38,1.56,1.7400000000000002,1.92,2.1,2.28,2.46,2.64,2.8200000000000003,{"y":3,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.04,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.34,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.32,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.21,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.03,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.94,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.98,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.89,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.7,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.68,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.84,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.81,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.66,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >